trending Market Intelligence /marketintelligence/en/news-insights/trending/rmos1i96p5mrazjiwubryw2 content esgSubNav
In This List

Tenax Therapeutics implements 1-for-20 reverse stock split

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Tenax Therapeutics implements 1-for-20 reverse stock split

Tenax Therapeutics Inc. implemented a 1-for-20 reverse split of its common shares to regain compliance with the Nasdaq Capital Market's minimum $1 bid price listing rule.

The Morrisville, N.C.-based specialty pharmaceutical's common stock will trade on a split-adjusted basis starting Feb. 26.

The split will reduce Tenax's outstanding common shares to about 1.4 million from 28.2 million.

Tenax noted that there is no assurance that the split will increase its bid price. The company has until March 12 to regain compliance with Nasdaq's listing requirements.